About
Natalie Yivgi-Ohana, PhD, is the co-founder, CEO, and board member of Minovia Therapeutics, an Israel-based clinical-stage biotech focused on mitochondrial cell therapies. Minovia says she has led the company since its 2012 incorporation, earned her PhD in Biochemistry from The Hebrew University in 2007, and completed postdoctoral work at the Weizmann Institute of Science through 2010. Her public profile centers on mitochondrial disease, cell therapy, biomarkers, and age-related mitochondrial dysfunction.
Areas of interest
mitochondrial biologymitochondrial diseasescell therapyrare diseasesbiomarkersaginglongevityregenerative medicinebiotech